Free Trial
NASDAQ:ASLN

ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis

ASLAN Pharmaceuticals logo
$0.60 0.00 (0.00%)
As of 04/30/2025

About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN)

Key Stats

Today's Range
$0.60
$0.60
50-Day Range
$0.60
$0.60
52-Week Range
$0.48
$25.44
Volume
N/A
Average Volume
122,322 shs
Market Capitalization
$1.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.00
Consensus Rating
Buy

Company Overview

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.

Receive ASLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ASLN Stock News Headlines

Donald Trump is about to free crypto from its chains …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
See More Headlines

ASLN Stock Analysis - Frequently Asked Questions

ASLAN Pharmaceuticals' stock was trading at $0.60 at the start of the year. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60.
View the best growth stocks for 2025 here
.

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.88) EPS for the quarter, beating analysts' consensus estimates of ($6.40) by $5.52. The company had revenue of $12 million for the quarter.

ASLAN Pharmaceuticals's stock reverse split on the morning of Wednesday, July 3rd 2024. The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

ASLAN Pharmaceuticals (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers.

Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Video Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
8/11/2023
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ASLN
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.00
High Stock Price Target
$72.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+11,900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-44,220,000.00
Pretax Margin
-290.83%

Debt

Sales & Book Value

Annual Sales
$12 million
Price / Cash Flow
N/A
Book Value
($6.50) per share
Price / Book
-0.09

Miscellaneous

Free Float
1,948,000
Market Cap
$1.23 million
Optionable
Optionable
Beta
1.40
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ASLN) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners